dm+d

Unassigned

New Medicines

Non-alcoholic steatohepatitis (NASH)

Information

New molecular entity
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

A therapeutic protein that mimics biological properties of fibroblast growth factor-21
Fatty liver disease is divided into alcohol-related fatty liver disease, and non-alcoholic fatty liver disease (NAFLD). The only difference between the two is the alcohol. A threshold of <20 g of alcohol per day in women and <30 g in men is usually used to allow a diagnosis of NAFLD. When inflammation is present, this becomes non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. In Europe prevalence of NAFLD is 20-30% and NASH is 5% [1].
Non-alcoholic steatohepatitis (NASH)
Subcutaneous